前列腺癌CT多期增强特征与血清PSA的相关性研究  

Characteristics of Multi-phase Enhanced CT of Prostate Cancer and Its Correlation of Serum PSA

作　　者：任蓬程 郑岗[1] 苏秀琼[1] 杨大梅[1] 

机构地区：[1]广东省惠州市中医医院CT室,广东惠州516001

出　　处：《中国CT和MRI杂志》2014年第8期72-74,共3页Chinese Journal of CT and MRI

基　　金：2010年惠州市医疗卫生科技计划项目(编号:2010Y 057)

摘　　要：目的探讨前列腺癌CT多期增强特征与血清PSA的相关性,以分析其诊断前列腺癌的价值。方法选择97例前列腺癌患者进行CT检查,观察其CT多期增强特征,同时检测其血清前列腺组织特异性抗原PSA的水平,并比较患者与良性前列腺患增生患者PSA水平的差异,分析前列腺癌CT多期增强特征与血清PSA的相关性。结果经CT检查发现,前列腺癌患者的动态增强开始时间为(37±12)s,早于对照组的(49±14)s;前列腺癌患者的最大信号强度为(146.45±75.21)%,早期强化率为(124.34±84.95)%,两者均高于对照组的(109.11±60.01)%和(75.33±42.46)%。两组患者这三个参数之间的差异均具有统计学意义(P<0.05)。前列腺癌组患者的血清PSA水平为(61.01±45.23)ng/ml,显著高于对照组患者的(9.12±8.67)ng/ml,差异具有统计学意义(P<0.05)。结论前列腺癌CT多期增强特征与血清PSA的水平呈明显的相关性,这可为前列腺癌的诊断、治疗提供新思路。Objective Investigate the characteristics of multi- phase enhanced CT of prostate cancer and its correlation with serum PSA, in order to analyze the diagnostic value of prostate cancer. Methods A total of 97 patients with prostate cancer underwent CT multi-phase scan, simultaneous detection of prostate-specific antigen in serum PSA levels and compared with patients with benign prostatic hyperplasia patients suffering from differences in PSA levels. prostate cancer CT analysis enhanced features multi-phase correlation with serum PSA. Results The CT dynamic contrast-enhanced start time of prostate cancer was （37±12）s, earlier than the control group （49±14） s;maximum signal strength of prostate cancer was （146.45±75.21）%, early strengthening was （124.34±84.95）%, both higher than the （109.11±60.01）% and （75.33±42.46）%, there were statistically significant （P〈0.05）. Prostate cancer patients with serum PSA level was （61.01±45.23） ng/ml, was significantly higher in patients （9.12±8.67） ng/ml, a statistically significant difference （P〈0.05）. Conclusion The multi-phase enhanced CT prostate cancer characteristics and serum PSA levels were significantly correlated, which provided new ideas for the future diagnosis and treatment of prostate cancer.

关 键 词：前列腺癌 CT 前列腺特异性抗原 前列腺增生 

分 类 号：R81[医药卫生—放射医学] R73[医药卫生—临床医学]